Publications by authors named "Avital Mizrahi"
Background: Current standard treatment for metastatic breast cancer (MBC) involves cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy, showing potential in enhancing anti-tumor immune responses.
Case Report: This report details a clinical case of MBC where palbociclib was co-administered with letrozole. The integration of allogeneic tumor vaccination to this treatment led to heightened interferon-γ production, expansion of CD8+ and NK cell populations, and positive delayed-type hypersensitivity reactions, indicating successful development of anti-tumor immunity.
Article Synopsis
- Tumor cell lines play a key role in studying cancer biology and responses to treatment, specifically focusing on how BRCA1/2 mutations impact sensitivity to the PARP inhibitor talazoparib.
- Researchers analyzed various BRCA1/2-mutant cell lines from human breast and ovarian cancer specimens to assess their growth response after treatment with talazoparib.
- The results showed a partial link between specific BRCA mutations and sensitivity to the drug, with some cell lines being sensitive while others, even with similar mutations, showed resistance, suggesting that loss of heterozygosity (LOH) may not always predict treatment efficacy.